Kintor Pharmaceutical Ltd. (stock code: 9939) reported revenue of RMB6.0 million for the six months ended 30 June 2025, compared to RMB0 million in the same period of 2024. The revenue increase was primarily attributed to global sales of the company's new high-end cosmetics brand KOSHINÉ. The group stated it will continue to explore strategies to further promote the commercialization of its cosmetic products worldwide. The company recorded a net loss of RMB83.3 million for the period, up RMB11.8 million or 16.5% from RMB71.5 million in the prior-year period. The increase in net loss was mainly due to higher research and development costs and increased marketing expenses. R&D costs rose by RMB9.3 million or 23.6%, reaching RMB48.6 million, as the company increased investment in its core dermatology pipelines KX-826 and GT20029, which are currently in various stages of clinical trials in China. Administrative expenses decreased by RMB8.7 million or 25.6% to RMB25.2 million, largely due to a reduction in employee benefit expenses and lower travel and office spending following a downsizing of staff. Kintor Pharmaceutical indicated that its cosmetics business is intended to support funding for drug R&D initiatives and provide market data for future pharmaceutical product strategies. The company remains committed to advancing its pipeline of five innovative drug candidates currently in phase I-III clinical trials.